Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer ...

Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...